Flowerkist Skin Care & Cosmetics Inc

Flowerkist Skin Care & Cosmetics — Merger or Acquisition (March 2023)

199 slides from Flowerkist Skin Care & Cosmetics's merger presentation, Mar 22, 2023

  1. Slide 1: Asset Purchase Agreement

    ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this “Agreement”) sets forth the principal terms on which ProVEDA Corporation (“ProVEDA”) and Flowerkist, Inc. (“Elowerkist”) have agreed with respect to the purchase (the “Transaction”) by ProVEDA from Flowerkist of all of Flowerkist’s assets

  2. Slide 2: Change of Control, Warrant and License to Transdermal Delivery System

    (ii) are referred to as a “Change of Control Transaction”). If, as of the date of the consummation of a Change of Control Transaction, the aggregate Purchase Price and Revenue Share payments received by Flowerkist are less than $10,000,000, then ProVEDA shall pay to Flowerkist contemporaneously with

  3. Slide 3: Non-compete, Expenses and Miscellaneous

    During the period beginning on the Signing Date and ending on the second (2nd) anniversary of the Initial Payment Deadline, Flowerkist shall not, and shall not allow any of its affiliates to, engage (whether as an owner, operator, manager, employee, officer, director, consultant, advisor, representa

  4. Slide 4: Signature and Termination Terms

    If the foregoing accurately reflects the basic terms and conditions of ProVEDA’s and Flowerkist’s agreement with respect to the Transaction, please sign and date one copy of this Agreement and return it to the undersigned. If this Agreement is fully executed, this Agreement shall remain in full forc

  5. Slide 5: Schedule: Purchased Assets

    Schedule 1 Purchased Assets (1) ProVEDA is acquiring the exclusive rights to all products associated with the wellness and therapeutic categories with regard to CBD enhanced topical solutions including but not limited to the products currently developed and referred to as Pain Management and Hand &

  6. Slide 6: Development of Polyherbal Cannabis Based Products

    DABUR Bivins —_ FOUNDATION = = Development of rationally designed polyherbal Cannabis based products with different therapeutic benefits Study data Version 1.1 16 March 2020 DABUR RESEARCH FOUNDATION 22, Site IV, Sahibabad Ghaziabad, U.P. 201010 INDIA www.daburresearch.in Confidential

  7. Slide 7: Therapeutic Areas

    me, \DABUR | RESEARCH — =~ —— = FOUNDATION =m i a Therapeutic areas Pain management Skin care Hand and foot care

  8. Slide 8: Our Strategy

    oes Our Strategy ft Rational selection of ingredients VY la NX Formulation development: Topical > S Extensive preclinical tests for efficacy and mechanism {- XN Permeability, penetration and safety tests y, (~ XN Formulation characterization ~ S * Knowledge and target based selection of ingredients

  9. Slide 9: Product Map

    ProductMap \ | J DABUR RESEARCH FOUNDATION = Formulation prototypes { Efficacy and \ permeability ormulation studies L: | In vitro efficacy tests | Lyi Skin permeability in vitro Efficacy in vitro } ( Permeability in vitro } ( Specifications and CoA } Comparator studies in vitro [ Rational selection

  10. Slide 10: CBD Sources

    = CBD sources a DABUR RCH FOUNDATION Concentrate \Sample Identification 1006 Laboratory Number 2019008857 Batch Number NA Matrix Concentrate [Analyzed Date 04/23/19 Extraction Date 04/23/19 %o mg/g 0.54% 5.43 ND ND 0.60% 5.98 59.70% 596.96 ND ND 1.34% 13.37 ND ND 1.81% 18.10 ND ND Delta 8-THC ND ND

  11. Slide 11: CBD Technology

    CBD Technology DABUR RESEARCH FOUNDATION =m

  12. Slide 12: CBD Technology Ingredients and Methodology

    a CBD technology ingredients and methodology , INGREDIENTS > Cholesterol Precirol ATO Span 60 Basil oil Eucalyptus oil Menthol CBD concentrate CBD Isolate Phospholipid PEG 400 PG Transcutol P Tween 80 Ks me, |DABUR ——<—in METHODOLOGY Lipid Phase: > Appropriate amount of Cholesterol, Precirol, and Sp

  13. Slide 13: Optimization and Characterization

    Optimization and Characterization DABUR RESEARCH FOUNDATION =m

  14. Slide 14: Optimization by Using Design Expert

    Optimization by using design expert Design of experiments (DOE) is a statistical technique for quickly optimizing performance of systems with known input variables. It starts with a screening experimental design test plan involving all the known factors that are suspected to affect the system's perf

  15. Slide 15: Optimization by Using Design Expert

    Optimization by using design expert eae, \DABUR — SS [RESEARCH = — JFOUNDATION i Factors Level | Low Level | High Level | Std. Dev. | Coding 0.0000) Actual 0.0000) Actual 20.00 0.0000 Actual Factor Name A LIPID CONCENTRATION 0.2000 0.1000 0.3000 B SURFACTANT CINCENTRATION 38.00 6.00 10.00 c HOMOGENI

  16. Slide 16: Optimization Contour Plots

    = )DABUR SS |RESEARCH OUNDATION a Optimization by using design expert- Contour plots — Contour plots showing simultaneous influence of independent variables on response parameters: (A) particle size, (B) zeta potential and (C) PDI of the formulated CBD technology within Box—Behnken experimental desi

  17. Slide 17: Linear Correlation Plots Actual vs Predicted

    me, |DABUR SS RESEARCH FOUNDATION a Linear correlation plots between actual and predicted values — ‘ETASIEE Fredited ys Actual Presiced vs. eral Coot sorts by vu of EAszE 1937 2257 * Figure 1 shows the linear plot between actual and predicted values and the corresponding residual plots for Zeta Size

  18. Slide 18: Technology Characterization: Particle Size Determination

    me, |DABUR ae . . oa SS RESEARCH Technology characterization — Particle size determination J FOUNDATION Zeta Size analysis is done by dynamic light scattering technique which measures the size of the particles suspended in a_ liquid. Particle size directly Malvern malvern ~W, Panalyticat ©, Banaiyti

  19. Slide 19: Transmission Electron Microscopy

    DABUR R RCH FOUNDATION a Technology Characterization- Transmission electron Microscopy — (cen is a technique in smn a high-energy electron beam created from an electron gun can strike a very thin sample. When the electron beam is transmitted through the sample an image is produced bearing the inform

  20. Slide 20: Pain Management

    Pain management DABUR RESEARCH FOUNDATION =m

  21. Slide 21: Pain Management: Formulation Development

    me, \DABUR — SS} RESEARCH == Pain management “=~ JrounpatioN = 8 — Formulation development

  22. Slide 22: CBD Technology for Pain Cream and Roll On

    a CBD technology for pain cream and roll on , INGREDIENTS > Cholesterol Precirol ATO Span 60 Basil oil Eucalyptus oil Menthol CBD concentrate CBD Isolate Phospholipid PEG 400 PG Transcutol P Tween 80 Ks me, |DABUR = | RESEARCH METHODOLOGY Lipid Phase: > Appropriate amount of Cholesterol, Precirol, a

  23. Slide 23: Rational Selection of Ingredients for Pain Cream and Roll On

    Rational selection of ingredients for Pain cream and Roll on = —= | RESEARCH Common names Scientific names Uses CBD Technology Spearmint Oil Eucalyptus oil Peppermint oil Camphor Clove bud oil Thyme oil Capsicum oleoresin oil Lavender oil Rosemary oil Myrrh oil Ginger oil Orange Sweet oil Chamomile

  24. Slide 24: Method of Preparation for Pain Cream

    ESEARCH Formulation development METHOD OF PREPARATION FOR PAIN CREAM >> Phase A: Step 1: All the oil phase ingredients were taken in a beaker and were heated. Phase B: Step 2: Appropriate amount of the water extracts and the actives were dissolved in distilled water. Step 3: CBD technology was then

  25. Slide 25: Efficacy and Permeability Assessments

    me, \DABUR SS} RESEARCH == Pain management “=~ JrounpatioN = 8 — Efficacy and permeability assessments

  26. Slide 26: Efficacy Tests In Vitro 1

    Efficacy tests in vitro..1 Rationale * COX-2 is an enzyme responsible for inflammation and pain. Inhibition of COX-2 plays key role in analgesic action. ¢ CBD derivatives have been reported as selective COX-2 inhibitors. ¢ Hence, inhibitory effect of CBD containing Pain formulations on COX-2 activit

  27. Slide 27: Efficacy Tests In Vitro 2: Pain Cream COX-2

    DABUR RESEARCH FOUNDATION [am i me Efficacy tests in vitro..2 ( COX-2 inhibition in vitro > Pain Cream 100 2 30 87.8 90.8 2 oI 80 Hy Vv 70 < o 58.5, 5 £ a 47.1 2 } cr ©£t 40 2s g 30 20.5 = 20 = 48 x - Ee | oO 0.01 0.05 0.1 15 15 75 Pain Cream XX ~ yy Pain Cream demonstrated analgesic effect by in vi

  28. Slide 28: Efficacy Tests In Vitro 3: Pain Roll-On COX-2

    DABUR RESEARCH a — ——) FOUNDATION [a i a Efficacy tests in vitro..3 ia COX-2 inhibition in vitro > Pain Roll-on 100 | 92.0 > 84. $ 90 A g 80 71.0 Y= 70 xo 5 60 54.0 ge 50 c=} ee 0 37.4 zw 30 2 20) Bs = 77 oO 0.01, 0.05 0.1 15 15 75 Pain Roll-On {ug/ml) Pain Roll-On demonstrated analgesic effect by i

  29. Slide 29: Analgesic Activity Using Rat Tail Flick Method 1

    me, |DABUR SS RESEARCH FOUNDATION om Efficacy of “Pain cream & Roll On” for Analgesic activity using Rat Tail flick Method..1 ~~~ Principle: The tail flick test is a thermal hyperalgesia test in which the tail of the animal is subjected to a heat source. Once the animal feels uncomfortable, removes

  30. Slide 30: Analgesic Activity Using Rat Tail Flick Method 2

    Efficacy of “Pain cream & Roll On” for Analgesic activity using Rat Tail flick Method..2 ( ae, )DABUR Tail Flick Reaction Time in Seconds GROUPS Omin | 30 min | 60 min | 120 min|240 min 15.3 a5e7) 15.6 15.4 15.2 Placebo, 200mg 0.56 0.34 0.49 0.45 0.66 15.0 29.3 27.3 23.5 19.0 Roll On, 200mg 0.62 3.0

  31. Slide 31: Analgesic Activity Using Rat Tail Flick Method 3

    mam Efficacy of “Pain cream & Roll On” for Analgesic activity using Rat Tail flick Method..3 % Analgesic Activity (Rat Tail Flick Model) Roll On, 200mg Pain Cream, 200mg = 30min 120 min 240 min me, |DABUR | RESEARCH FOUNDATION * Topical application with “Roll on” cream demonstrated significant (p<0.

  32. Slide 32: Permeability Tests In Vitro 1

    Permeability tests in vitro..1 * Rationale * Evaluation of permeation for transdermal or topical formulations, for which the drug is released through the skin, is critical to establish bioavailability and thereby make an approximation of the effectiveness. Additionally, it is important to test perfo

  33. Slide 33: Permeability Tests In Vitro 2

    — eos S= — Pp A ‘ 5 — JFOUNDATION = ermeability tests in vitro..2 | y nl Results = Pain cream 62 (Innovator) £ 250.00 EY pga ic *« CBD cumulative permeation profile from TDDS is shown in ree i inst ti 3 450.00 figure (permeated amount plotted against time) ® 100.00 * Total CBD amount (yg + SD) perme

  34. Slide 34: Permeability Tests In Vitro 3

    me, |DABUR = | RESEARCH -—=~ = — JFOUNDATION = i a Permeability tests in vitro..3 * In-vitro permeation experiments reveals that, higher concentrations of CBD (240 ng/ml) was achieved in * Interpretation receptor solution (which is indicative of systemic circulation) at very initial time interval (1

  35. Slide 35: Penetration Ex Vivo: Rat Skin

    (conto Imaging: contoeat es using this technique. yy Penetration ex vivo — Rat skin microscopy is a powerful tool for generating high-resolution images and 3-D reconstructions of a specimen. This technique is used to investigate topical formulations for both penetration & penetration depth in vitro

  36. Slide 36: Penetration Ex Vivo: Guinea Pig Skin

    Penetration ex vivo — Guinea pig skin = A. Pain cream 6+2 (guinea pig) Depth 330m B. Charlotte's web (guinea pig) Depth 150um C. CBD Medic (guinea pig) Depth 135um pb. Myaderm ( guinea pig) onoentn 60ym Result: Confocal microscopy of guinea pig skin with z-stack (penetration depth profile) image at

  37. Slide 37: Formulation Characterization

    me, \DABUR — SS} RESEARCH == Pain management “=~ JrounpatioN = 8 — Formulation characterization

  38. Slide 38: Formulation Characterization

    Formulation Characterization ( PHYSICOCHEMICAL > PROPERTY: > Description: Light brown colour soft mass. > Solubility: Soluble in water > pH :-4.75 > Foreign Matter Passes the test. > Total Ash: 0.37 % w/w qe Viscosity at 25°C: 48333 i, ( HEAVY METAL > Lead: Below quantification limit Cadmium: Below

  39. Slide 39: HPLC Method for CBD Content

    kes R ——, SSS RESEARCH sam HPLC Method for CBD content IE * Flowrate -1 ml/min * Mobile phase - Channel A - (0.1% formic acid in ACN),Channel B — (0.1% Formic acid In Water) * — Injection volume - 25 ul * Column temperature - 50 °C * Detector wavelength - 230 nm * Runtime - 18 min * Column - Inertis

  40. Slide 40: HPLC Analysis for CBD Content for Pain Cream

    omy HPLC analysis for CBD content for Pain cream DARN ASIO=2904 Rsiaatt me, |DABUR SS RESEARCH FOUNDATION Chromatogram Of CBD Standard 4004 3507 3004 Signal; DAD1A,Sig=230,4 Ref= P| Name — RT {min Area 150. 14,82 4544.24 100: 50: Sum 4544 2066 o- i rr ee Ce Tinve (min) Chromatogram Of PAIN 6+2 DADA

  41. Slide 41: Texture Analysis

    Texture Analysis DABUR SEARCH FOUNDATION oa i m eit P| 1 A 4 } i “ a Pain Cream Sample Pain Cream Reference sample Pain Cream comparison sample vs Reference sample Results: Test iD Firmness Stickiness Work of shear Index of viscosity ‘3 3 g-sec g-sec Pain cream reference pain cream Dabur Peak Positi

  42. Slide 42: Stability - Ongoing

    me, |DABUR RESEARCH = JFOUNDATIN i === Stability - Ongoing = Stability of Pain Cream Batch No. DRF-FD/| ~~ 001- Stability Date 17-Dec-19 Mfg Date 11-Dec-19 Accelerated condition Intermediate condition Real Time condition 40°C/75% 302C/65% 252C/60% S.No. | Characterization | Initial 1M 3M 6M 3M 6M 9M

  43. Slide 43: Safety Assessment

    me, \DABUR — SS} RESEARCH == Pain management “=~ JrounpatioN = 8 — Safety assessment

  44. Slide 44: Safety Tests In Vitro: Skin Irritation Using Human Reconstructed Skin

    Safety tests in vitro — skin irritation using human reconstructed skin Rationale ¢ Assessment of viability in 3-D reconstructed skin is used to determine the skin irritation potential in vitro (OECD439). Study design * Test Item was applied to EpiDerm tissues and incubated for 1 h. ¢ After washing,

  45. Slide 45: Skin Irritation Using 3-D Skin: Pain Cream

    me, |DABUR SS} RESEARCH FOUNDATION Safety tests in vitro — skin irritation using 3-D skin — Pain Cream = y 8 i (— Pain Cream >) 110 100 100 LL in a te ih 90 2 80 go” © 2 60 3 & 50 -- Peer eeee. eee 3 — 40 - 30 20 7.8 10 5 PF NC (Untreated) Pc (SDS) Pain Cream \ y, Pain Cream demonstrated 48.5% tissu

  46. Slide 46: Skin Irritation Using 3-D Skin: Pain Roll-On

    Safety tests in vitro — skin irritation using 3-D skin — Pain Roll-On P \ Tissue viability (wrt NC) 110 100 Qu8 © eeo6o6 50 20 10 “roo Pain Roll-On NC (Untreated) —_ - = a 78 P| PC (SDS) Pain Roll-On wy me, |DABUR a | RESEARCH -—=~ — — JFOUNDATION = i Pain Roll-On demonstrated 48% tissue viability i

  47. Slide 47: Ocular Irritation HET-CAM

    = | RESEARCH = es R ey ~~ Jrounpation = Safety tests in vitro — ocular irritation-HET-CAM —— Rationale + Assessment of ocular irritant potential Pain y } Cream 62 performed using HET-CAM (Hen's Egg es on An) im Test - Chorioallantoic Membrane) assay in { Ay accordance with INVITTOX n°96. \ \ \ = ~wS

  48. Slide 48: Ocular Irritation HET-CAM: Pain Cream

    me, |DABUR ——— RCH FOUNDATION = Safety tests in vitro — ocular irritation-HET—CAM - Pain Cream = CAMs reaction 0.1% SDS CAMs reaction 0.5% SDS CAMs reaction 1% SDS 0ee@ CAMs reaction Pain Cream 62 3 min exposure 30 sec exposure (Collective Score 16) (Collective Score 14) gq: © <= CAMs treated with t

  49. Slide 49: Ocular Irritation HET-CAM: Pain Roll On

    e PABUR —— RCH Safety tests in vitro — Ocular irritation-HET-CAM - Pain Roll On FOUNDATION CAMs reaction 0.1% SDS CAMs reaction 0.5% SDS CAMs reaction 1% SDS >») é a A [ CAMs reaction Pain Roll On 62 3 min exposure 30 sec exposure (Collective Score 14) (Collective Score 13) Comer] Came] ae) Cae) / C

  50. Slide 50: Comparators

    Comparators Test product CBD content In vitro COX inhibition 1C50 (ug/ml) In vivo efficacy (% Analgesic activity) Permeation in vitro Flux (ug/(cm?"hr) —= JFOUNDATION = penetration ex vivo (guinea Pain Cream Pain Roll-On Myaderm Tl vs comparator Charlotte's web Tl vs comparator CBD Medic Tl vs compa

  51. Slide 51: Product Claims and Attributes

    DABUR RESEARCH FOUNDATION [am 7 =a : . a Product Claims and attributes a Good flux rate indicating permeation of higher CBD content across Permeability i skin XY a Efficacy in vitro f Good analgesic effect by inhibition of COX-2 activity | XY uy a a Efficacy in vivo | Good analgesic effect by pain r

  52. Slide 52: Skin Health

    Skin health DABUR RESEARCH FOUNDATION =m

  53. Slide 53: Day Cream

    Day Cream DABUR RESEARCH FOUNDATION =m

  54. Slide 54: CBD Technology for Antiaging Day Cream

    CBD TECHNOLOGY FOR ANTIAGING DAY CREAM Va INGREDIENTS ~ Cholesterol Precirol ATO Span 60 CBD concentrate CBD Isolate PEG 400 PG Transcutol P Tween 80 Water XN me, |DABUR SS RESEARCH METHODOLOGY Lipid Phase: > Appropriate amount of Cholesterol, Precirol, and Span 60 were taken and heated until the co

  55. Slide 55: Rational Selection of Ingredients for Day Cream

    Rational selection of ingredients for Day Cream = —= —- DABUR | RESEARCH Common names Scientific names USES CBD Technology - has good anti-inflammatory property Titanium Dioxide - Acts as a mineral UV filter Ginseng water extract Panax ginseng Stimulates skin metabolism by removing free radical from

  56. Slide 56: Manufacturing Procedure of Day Cream

    me, |DABUR = RESEARCH = JFOUNDATION = i Formulation development MANUFACTURING PROCEDURE OF DAY CREAM Step 1: All the water phase ingredients were accurately weighed and dissolved in half the amount of distilled Phase A: water and slightly heated for completely dissolution. Step 2: To this mixture ge

  57. Slide 57: Efficacy Tests In Vitro

    Efficacy tests in vitro Rationale ¢ Fibroblasts are key cells that contribute to a healthy skin. Their turnover, secretion of ECM (collagen, elastin, HA) maintains the skin health. Study design * Test Item was dissolved in DMSO to prepare stock solution. * The stock was diluted to achieve final test

  58. Slide 58: Fibroblasts Proliferation and Collagen Synthesis

    me, \DABUR => | RESEARCH FOUNDATION Efficacy tests in vitro — Fibroblasts proliferation 28 466 ae F 4 0 r 001 oot nooo. oa % Increase in fibroblasts proliferation (wrt Untreated) 6 8 886 8 8 ‘Anti-aging Day Cream (ug/ml) Collagen Boas z 5 eo 581 BE os azo éz 0 £2 x0 12 2 £ 10 ® 0 8.00001 o.oo oon An

  59. Slide 59: Formulation Characterization

    = |DABUR S| RESEARCH — (= JFOUNDATION = = > ( MICROBIAL CONTAMINATION: Formulation Characterization ( PHYSICOCHEMICAL > PROPERTY: > Description: Off white colour » Total Bacterial count, cfu/g.: alt HESS Less than 10 nee > Total fungal count,cfu/g: Less > Solubility: Soluble in water than 10 » pH :-

  60. Slide 60: HPLC Analysis for CBD Content for Day Cream

    — ee )DABUR Bivins = JFOUNDATION = mm HPLC analysis for CBD content for Day cream — DADIASY=204 REIDR Chromatogram Of CBD Standard mi 400- 3504 Signal: DAD1A,Sig=230,4 Ref= 3004 Name = - RT (rie) Aroa gor 150: 14,86 5089,23 ed sum 5089,2323 ts 50° . ae 1 7 a 4 5 6 7 5 8 10 n w 13 “4 16 16 v7 aL Tine

  61. Slide 61: Safety Tests In Vitro: Skin Irritation Using 3-D Skin

    Rationale ¢ Assessment of viability in 3-D reconstructed skin is used to determine the skin irritation potential in vitro (OECD439). Study design * Test Item was applied to EpiDerm tissues and incubated for 1 h. ¢ After washing, tissues were allowed to recover for 24h. * Viability of tissue was dete

  62. Slide 62: Skin Irritation Using 3-D Skin: Day Cream

    me, |DABUR = | RESEARCH = FOUNDATION =m i === Safety tests in vitro — skin irritation using 3-D skin SS >» ( Anti-aging Day Cream » Rationale to a _ _ ¢ Assessment of viability in 3- 90 D reconstructed skin is used zB 0 to determine the skin 3 8 ew irritation potential in vitro gy g o , re ni (OECD4

  63. Slide 63: Safety Tests In Vitro: Ocular Irritation HET-CAM

    Safety tests in vitro — ocular irritation-HET—CAM Rationale + Assessment of ocular irritant potential Pain Cream 62 performed using HET-CAM (Hen's Egg Test - Chorioallantoic Membrane) assay in accordance with INVITTOX n°96. Study design * Test Item was applied for 3 min followed by washing followed

  64. Slide 64: Ocular Irritation HET-CAM: Day Cream

    ee |DABUR SS} RESEARCH FOUNDATION i CAMs reaction 0.1% SDS CAMs reaction 0.5% SDS CAMs reaction 1% SDS >» Safety tests in vitro — Ocular irritation-HET-CAM CAMs reaction Antiaging Day Cream 3 min exposure | (Collective score 9) . Scoring:2 Scoring: 1 CAMs treated with the Anti-aging Day Cream for 3

  65. Slide 65: Comparators

    DABUR RESEARCH FOUNDATION = Comparators — CBD In vitro fibroblasts utyitro Comparator Test Item = : Collagen content proliferation : synthesis Anti-aging Day 2.20% w/v + 52.8% + 68.8% Cream Lord Jones + 43.9% + 61.9%

  66. Slide 66: Product Claims and Attributes

    DABUR RESEARCH FOUNDATION a Product Claims and attributes —

  67. Slide 67: Night Cream

    Night Cream DABUR RESEARCH FOUNDATION =m

  68. Slide 68: CBD Technology for Night Cream

    eae, \DABUR > eseancu CBD TECHNOLOGY FOR NIGHT CREAM “oN i METHODOLOGY ( » Lipid Phase: > Appropriate amount of Cholesterol, Precirol, and Span 60 were taken and INGREDIENTS heated until the content gets melted. Cholesterol . Drug Phase Precirol ATO > CBD concentrate and isolate were dissolved in pr

  69. Slide 69: Rational Selection of Ingredients for Night Cream

    Rational selection of ingredients for Night cream = —= DABUR | RESEARCH FOUNDATION =m Common Names Scientific names USES CBD Technology Elage Ginseng water extract Acacia berry water extract Guggul water extract Curcumin water extract Grapeseed water extract Manjishtha water extract Pomegranate wate

  70. Slide 70: Manufacturing Procedure of Night Cream

    me, |DABUR RESEARCH = — = JFOUNDATION = Formulation development MANUFACTURING PROCEDURE OF NIGHT CREAM Phase A: Step 1: All the water phase ingredients and actives were accurately weighed and dissolved in distilled water and slightly heated for completely dissolution. Step 2: To this mixture gelling

  71. Slide 71: Efficacy Tests In Vitro

    Efficacy tests in vitro Rationale ¢ Fibroblasts are key cells that contribute to a healthy skin. Their turnover, secretion of ECM (collagen, elastin, HA) maintains the skin health. Study design * Test Item was dissolved in DMSO to prepare stock solution. * The stock was diluted to achieve final test

  72. Slide 72: Efficacy Tests In Vitro

    Efficacy tests in vitro Fibroblasts proliferation 26 a2 252 L - 0 |_| 2 onoo01 oor 003 on % Increase in fibroblasts proliferation (wrt Untreated) 5B B88 8B Anti-aging Night Cream Ge/m)) Collagen Hi = 787 - @ fs ™ 9 gg 2 os Zi 9 85 « fz 25 2 2 2 wo & o 000. oo. oot ‘Anti-aging Night Cream (he/ml) = D

  73. Slide 73: Formulation Characterization

    Formulation Characterization (— PHYSICOCHEMICAL > PROPERTY: > Description: Off white colour soft mass. > Solubility: Soluble in water > pH :- 4.82 > Foreign Matter Passes the test. > Total Ash: 0.20 % w/w q ye Viscosity at 25°C: 43333 a, HEAVY METAL , Lead: Below quantification limit Cadmium: Below

  74. Slide 74: HPLC Analysis for CBD Content for Night Cream

    HPLC analysis for CBD content for Night cream Chromatogram Of CBD Standard Signal: VWD14,Wavel Name RT (min) | Area 7 14.55 4697.39 Sum 4697.29 — | 7 Chromatogram Of Night cream Signal: VWDI1A,Wavel Name RT (min) [Ares 14.84 2291,68 Sum 2281.67 59 VWD 1A Wavilengit=236 ni FOUNDATION [am i tf st Ser

  75. Slide 75: Texture Analysis

    Texture Analysis Force ig) ° re eee © © : ©. ° = ” | Sama y : ee j 2 Tine ee) al i, © = “2 oa “o Night Cream Sample Night Cream Reference sample Night Cream comparison sample vs Reference sample Results: Test ID Firmness Stickiness Work of shear Index of viscosity & c- g-sec g.sec Peak Positive Forc

  76. Slide 76: Stability - Ongoing

    Stability - Ongoing me, |DABUR SS RESEARCH FOUNDATION Stability of Night Cream Batch No. DRF-FD/AAN5-CBD/001-19 Stability Date | 18-Dec-19 Mfg Date 18-Dec-19 Characterizat S.No. ion Initial 402C/75% 302C/65% 252C/60% 1M 3M 6M 3M 6M OM 3M 6M 9M 12M Off [white Description |colour por 18-Jan-20 . 18-Ma

  77. Slide 77: Safety Tests In Vitro: Skin Irritation Using 3-D Skin

    Rationale ¢ Assessment of viability in 3-D reconstructed skin is used to determine the skin irritation potential in vitro (OECD439). Study design * Test Item was applied to EpiDerm tissues and incubated for 1 h. ¢ After washing, tissues were allowed to recover for 24h. * Viability of tissue was dete

  78. Slide 78: Skin Irritation Using 3-D Skin: Night Cream

    Safety tests in vitro — skin irritation using 3-D skin ee |DABUR Sa | RESEARCH -s~ — = JFOUNDATION = Bi ia XN Tissue viability {wrt NC) Anti-aging Night Cream 100 NC (Untreated) PC (SDS) 102.7 Antiaging Night cream ~ y, Anti-aging Night Cream demonstrated 102.7% tissue viability in 3-D reconstructed

  79. Slide 79: Safety Tests In Vitro: Ocular Irritation HET-CAM

    Safety tests in vitro — ocular irritation-HET—CAM Rationale + Assessment of ocular irritant potential Pain Cream 62 performed using HET-CAM (Hen's Egg Test - Chorioallantoic Membrane) assay in accordance with INVITTOX n°96. Study design * Test Item was applied for 3 min followed by washing followed

  80. Slide 80: Ocular Irritation HET-CAM: Night Cream

    me, |DABUR | RESEARCH FOUNDATION a Safety tests in vitro — Ocular irritation-HET-CAM ( CAMs reaction 0.1% SDS CAMs reaction 0.5% SDS CAMs reaction 1% SDS >» ~ CAMs reaction Antiaging Night Cream 3 min exposure (Collective score 7) a Scoring: 1 Scoring:2 CAMs treated with the Anti-aging Night Cream f

  81. Slide 81: Slide 81

  82. Slide 82: Slide 82

  83. Slide 83: Slide 83

  84. Slide 84: Slide 84

  85. Slide 85: Slide 85

  86. Slide 86: Slide 86

  87. Slide 87: Slide 87

  88. Slide 88: Slide 88

  89. Slide 89: Slide 89

  90. Slide 90: Slide 90

  91. Slide 91: Slide 91

  92. Slide 92: Slide 92

  93. Slide 93: Slide 93

  94. Slide 94: Slide 94

  95. Slide 95: Slide 95

  96. Slide 96: Slide 96

  97. Slide 97: Slide 97

  98. Slide 98: Slide 98

  99. Slide 99: Slide 99

  100. Slide 100: Slide 100

  101. Slide 101: Slide 101

  102. Slide 102: Slide 102

  103. Slide 103: Slide 103

  104. Slide 104: Slide 104

  105. Slide 105: Slide 105

  106. Slide 106: Slide 106

  107. Slide 107: Slide 107

  108. Slide 108: Slide 108

  109. Slide 109: Slide 109

  110. Slide 110: Slide 110

  111. Slide 111: Slide 111

  112. Slide 112: Slide 112

  113. Slide 113: Slide 113

  114. Slide 114: Slide 114

  115. Slide 115: Slide 115

  116. Slide 116: Slide 116

  117. Slide 117: Slide 117

  118. Slide 118: Slide 118

  119. Slide 119: Slide 119

  120. Slide 120: Slide 120

  121. Slide 121: Slide 121

  122. Slide 122: Slide 122

  123. Slide 123: Slide 123

  124. Slide 124: Slide 124

  125. Slide 125: Slide 125

  126. Slide 126: Slide 126

  127. Slide 127: Slide 127

  128. Slide 128: Slide 128

  129. Slide 129: Slide 129

  130. Slide 130: Slide 130

  131. Slide 131: Slide 131

  132. Slide 132: Slide 132

  133. Slide 133: Slide 133

  134. Slide 134: Slide 134

  135. Slide 135: Slide 135

  136. Slide 136: Slide 136

  137. Slide 137: Slide 137

  138. Slide 138: Slide 138

  139. Slide 139: Slide 139

  140. Slide 140: Slide 140

  141. Slide 141: Slide 141

  142. Slide 142: Slide 142

  143. Slide 143: Slide 143

  144. Slide 144: Slide 144

  145. Slide 145: Slide 145

  146. Slide 146: Slide 146

  147. Slide 147: Slide 147

  148. Slide 148: Slide 148

  149. Slide 149: Slide 149

  150. Slide 150: Slide 150

  151. Slide 151: Slide 151

  152. Slide 152: Slide 152

  153. Slide 153: Slide 153

  154. Slide 154: Slide 154

  155. Slide 155: Slide 155

  156. Slide 156: Slide 156

  157. Slide 157: Slide 157

  158. Slide 158: Slide 158

  159. Slide 159: Slide 159

  160. Slide 160: Slide 160

  161. Slide 161: Slide 161

  162. Slide 162: Slide 162

  163. Slide 163: Slide 163

  164. Slide 164: Slide 164

  165. Slide 165: Slide 165

  166. Slide 166: Slide 166

  167. Slide 167: Slide 167

  168. Slide 168: Slide 168

  169. Slide 169: Slide 169

  170. Slide 170: Slide 170

  171. Slide 171: Slide 171

  172. Slide 172: Slide 172

  173. Slide 173: Slide 173

  174. Slide 174: Slide 174

  175. Slide 175: Slide 175

  176. Slide 176: Slide 176

  177. Slide 177: Slide 177

  178. Slide 178: Slide 178

  179. Slide 179: Slide 179

  180. Slide 180: Slide 180

  181. Slide 181: Slide 181

  182. Slide 182: Slide 182

  183. Slide 183: Slide 183

  184. Slide 184: Slide 184

  185. Slide 185: Slide 185

  186. Slide 186: Slide 186

  187. Slide 187: Slide 187

  188. Slide 188: Slide 188

  189. Slide 189: Slide 189

  190. Slide 190: Slide 190

  191. Slide 191: Slide 191

  192. Slide 192: Slide 192

  193. Slide 193: Slide 193

  194. Slide 194: Slide 194

  195. Slide 195: Slide 195

  196. Slide 196: Slide 196

  197. Slide 197: Slide 197

  198. Slide 198: Slide 198

  199. Slide 199: Slide 199

Flowerkist Skin Care & Cosmetics — Merger or Acquisition (March 2023) on 6ix